Immunovia’s PanFAM-1: The largest study of hereditary pancreatic cancer risk, gathers momentum in the US
Two additional centers in New York and Chicago join the drive to validate the IMMrayTM PanCan-d test designed for early detection of pancreatic cancer LUND, SWEDEN ― According to the American Cancer Society, as many as 10% of pancreatic cancers are caused by inherited genetic mutations. Furthermore, these mutations may increase risk of other cancers such as breast, ovarian and skin and eye melanomas. PanFAM-1 is the largest prospective study to date, that is looking at early diagnosis in high-risk individuals with Familial Pancreatic Cancer (FPC). Designed to validate Immunovia ́s